Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
December 14, 2021
Lymphogranuloma venereum
Eric J Eckbo, Malcolm Hedgcock, Troy Grennan
Open Forum Infectious Diseases
|
November 3, 2025
Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline
Karam Mounzer, Jihad Slim, Moti Ramgopal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 26, 2024
Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1)
Karam Mounzer, Jihad Slim, Moti Ramgopal, et al.
Lancet (London, England)
|
February 28, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial
Chloe Orkin, Peter J Ruane, Malcolm Hedgcock, et al.
Viruses
|
May 25, 2024
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy
Sneha Datwani, Rebecca Kalikawe, Rachel Waterworth, et al.
AIDS (London, England)
|
December 22, 2022
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy
Hope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 21, 2021
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
Zabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 30, 2022
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses
Hope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
NPJ Vaccines
|
March 1, 2022
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
Zabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
The Journal of Infectious Diseases
|
June 7, 2022
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses
Hope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
|
December 14, 2021
Lymphogranuloma venereum
Eric J Eckbo, Malcolm Hedgcock, Troy Grennan
Open Forum Infectious Diseases
|
November 3, 2025
Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline
Karam Mounzer, Jihad Slim, Moti Ramgopal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 26, 2024
Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1)
Karam Mounzer, Jihad Slim, Moti Ramgopal, et al.
Lancet (London, England)
|
February 28, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial
Chloe Orkin, Peter J Ruane, Malcolm Hedgcock, et al.
Viruses
|
May 25, 2024
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy
Sneha Datwani, Rebecca Kalikawe, Rachel Waterworth, et al.
AIDS (London, England)
|
December 22, 2022
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy
Hope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 21, 2021
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
Zabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 30, 2022
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses
Hope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
NPJ Vaccines
|
March 1, 2022
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
Zabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
The Journal of Infectious Diseases
|
June 7, 2022
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses
Hope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Page
of 1